SG11202102641RA - Tlr8 agonist - Google Patents

Tlr8 agonist

Info

Publication number
SG11202102641RA
SG11202102641RA SG11202102641RA SG11202102641RA SG11202102641RA SG 11202102641R A SG11202102641R A SG 11202102641RA SG 11202102641R A SG11202102641R A SG 11202102641RA SG 11202102641R A SG11202102641R A SG 11202102641RA SG 11202102641R A SG11202102641R A SG 11202102641RA
Authority
SG
Singapore
Prior art keywords
tlr8 agonist
tlr8
agonist
Prior art date
Application number
SG11202102641RA
Other languages
English (en)
Inventor
Zhe Cai
Fei Sun
Charles Z Ding
Shuhui Chen
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of SG11202102641RA publication Critical patent/SG11202102641RA/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/20Antivirals for DNA viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
SG11202102641RA 2018-09-19 2019-09-19 Tlr8 agonist SG11202102641RA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201811094969 2018-09-19
PCT/CN2019/106687 WO2020057604A1 (zh) 2018-09-19 2019-09-19 Tlr8激动剂

Publications (1)

Publication Number Publication Date
SG11202102641RA true SG11202102641RA (en) 2021-04-29

Family

ID=69888288

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202102641RA SG11202102641RA (en) 2018-09-19 2019-09-19 Tlr8 agonist

Country Status (11)

Country Link
US (1) US12054482B2 (https=)
EP (1) EP3854794B1 (https=)
JP (1) JP7498702B2 (https=)
KR (1) KR102856089B1 (https=)
CN (2) CN112805283B (https=)
AU (1) AU2019344868B2 (https=)
CA (1) CA3112953A1 (https=)
ES (1) ES2999323T3 (https=)
PH (1) PH12021550601A1 (https=)
SG (1) SG11202102641RA (https=)
WO (1) WO2020057604A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11202102641RA (en) 2018-09-19 2021-04-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Tlr8 agonist
EP4122931B1 (en) * 2020-03-18 2025-07-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Crystalline form of tlr8 agonist
CN116472047B (zh) * 2021-11-05 2025-06-17 中国医药研究开发中心有限公司 芳胺类衍生物及其制备方法和医药用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0503506D0 (en) 2005-02-21 2005-03-30 4 Aza Bioscience Nv Substituted pyrido(2,3-d) pyrimidine derivatives and pharmaceutical compositions useful as medicines for the treatment of autoimmune disorders
PT2268618E (pt) 2008-03-03 2015-10-12 Novartis Ag Compostos e composições moduladores da actividade tlr
SG194852A1 (en) 2011-05-18 2013-12-30 Janssen R & D Ireland Quinazoline derivatives for the treatment of viral infections and further diseases
WO2013022766A1 (en) 2011-08-05 2013-02-14 Flynn Gary A Preparation and methods of use for ortho-aryl 5- membered heteroaryl-carboxamide containing multi-targeted kinase inhibitors
EP2925729B1 (en) 2012-11-16 2017-10-18 Janssen Sciences Ireland UC Heterocyclic substituted 2-amino-quinazoline derivatives for the treatment of viral infections
WO2016141092A1 (en) 2015-03-04 2016-09-09 Gilead Sciences, Inc. Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds
EP3507288B1 (en) 2016-09-02 2020-08-26 Gilead Sciences, Inc. 4,6-diamino-pyrido[3,2-d]pyrimidine derivaties as toll like receptor modulators
CN109923106B (zh) 2016-09-02 2022-09-13 吉利德科学公司 toll样受体调节剂化合物
SG11202102641RA (en) 2018-09-19 2021-04-29 Chia Tai Tianqing Pharmaceutical Group Co Ltd Tlr8 agonist

Also Published As

Publication number Publication date
JP7498702B2 (ja) 2024-06-12
EP3854794A1 (en) 2021-07-28
JP2022501350A (ja) 2022-01-06
AU2019344868A1 (en) 2021-04-15
AU2019344868B2 (en) 2024-06-27
ES2999323T3 (en) 2025-02-25
US12054482B2 (en) 2024-08-06
CN112805283A (zh) 2021-05-14
WO2020057604A1 (zh) 2020-03-26
PH12021550601A1 (en) 2021-11-29
KR102856089B1 (ko) 2025-09-04
CN115650979A (zh) 2023-01-31
KR20210060567A (ko) 2021-05-26
CA3112953A1 (en) 2020-03-26
US20210371414A1 (en) 2021-12-02
EP3854794A4 (en) 2022-06-15
CN112805283B (zh) 2022-09-20
EP3854794B1 (en) 2024-11-27

Similar Documents

Publication Publication Date Title
DK3793565T3 (en) Mcl-1-inhibitorer
DK3467457T3 (en) Vibrationssensor
DK3759096T3 (en) Cd73-inhibitorer
CA185383S (en) Casque
CA185382S (en) Casque
CA185384S (en) Casque
PT3810587T (pt) Alcoxipiridinilindolsulfonamidas substituídas
CA185385S (en) Casque
DK3872428T3 (en) Indvendigt luftstyringssystem
DK3773537T3 (en) Stat3-hæmmere
LT3599836T (lt) Tiektuvas
DK3554057T3 (en) Audioheadsetsystem
DK3768830T3 (en) Cancerterapi
CA184992S (en) Uroflowmeter
DK3613739T3 (en) Integrin-antagonister
DK3753395T3 (en) Indvendigt luftstyringssystem
CA184989S (en) Uroflowmeter
DK3633783T3 (en) Universal-powerbank
DK3801538T3 (en) Tlr7-agonister
SG11202102641RA (en) Tlr8 agonist
EP3875451A4 (en) TLR8 AGONIST
DK3768906T3 (en) Træmodul
DK3650069T3 (en) Trakeostomiventil
DK3578923T3 (en) Navigationssystem
ZA201907529B (en) Feeder